First Light Asset Management LLC Purchases Shares of 95,955 Abivax SA Sponsored ADR $ABVX

First Light Asset Management LLC acquired a new position in Abivax SA Sponsored ADR (NASDAQ:ABVX) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 95,955 shares of the company’s stock, valued at approximately $8,147,000. First Light Asset Management LLC owned 0.12% of Abivax at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. UBS Group AG raised its stake in shares of Abivax by 2,561.0% in the third quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock valued at $378,761,000 after purchasing an additional 4,293,606 shares in the last quarter. Darwin Global Management Ltd. bought a new position in Abivax in the third quarter worth $263,698,000. Octagon Capital Advisors LP boosted its stake in Abivax by 3.0% during the second quarter. Octagon Capital Advisors LP now owns 1,267,000 shares of the company’s stock worth $9,693,000 after buying an additional 37,000 shares in the last quarter. Millennium Management LLC increased its holdings in Abivax by 6.0% in the 1st quarter. Millennium Management LLC now owns 987,414 shares of the company’s stock valued at $6,171,000 after buying an additional 56,235 shares during the period. Finally, Baker BROS. Advisors LP bought a new stake in Abivax in the 3rd quarter valued at $74,355,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

Wall Street Analyst Weigh In

ABVX has been the subject of a number of analyst reports. Citigroup reaffirmed a “market outperform” rating on shares of Abivax in a report on Thursday, January 8th. Citizens Jmp upped their target price on shares of Abivax from $114.00 to $131.00 and gave the company a “market outperform” rating in a research note on Tuesday, December 16th. Piper Sandler reissued an “overweight” rating and issued a $142.00 price target on shares of Abivax in a research report on Tuesday, December 16th. Guggenheim restated a “buy” rating and set a $175.00 price target on shares of Abivax in a research note on Thursday, December 18th. Finally, Morgan Stanley lifted their price objective on Abivax from $101.00 to $145.00 and gave the company an “overweight” rating in a report on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $134.75.

Abivax Stock Down 1.3%

Shares of ABVX opened at $115.50 on Monday. The company has a market capitalization of $9.13 billion, a P/E ratio of -27.63 and a beta of 1.01. Abivax SA Sponsored ADR has a one year low of $4.77 and a one year high of $148.83. The business’s 50 day simple moving average is $118.99 and its 200-day simple moving average is $109.10. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.86 and a quick ratio of 7.86.

Abivax (NASDAQ:ABVX) last released its quarterly earnings results on Monday, December 15th. The company reported ($2.46) earnings per share for the quarter. The company had revenue of ($4.92) million during the quarter. As a group, sell-side analysts predict that Abivax SA Sponsored ADR will post -2.83 EPS for the current fiscal year.

Abivax Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.